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Abstract : Gastric cancers （GC） with methylation of multiple CpG islands have a 
CpG island methylator phenotype （CIMP） and they can have different biological 
features.  The aim of this study was to investigate the DNA methylation status of 
GCs and its association with their clinicopathological features.  We evaluated the 
methylation status of four genes （MINT1, MINT2, MINT25 and MINT31） in 105 
primary GCs using bisulte-pyrosequencing analysis.  We classied tumors as CIMP-
high （CIMP-H）, CIMP-low （CIMP-L） or CIMP-negative （CIMP-N） based on the 
methylation of MINT1, MINT2, MINT25, and MINT31.  Overall, the prevalence 
of CIMP-H, CIMP-L and CIMP-N was 22% （23/105）, 52% （55/105） and 26% 
（27/105）, respectively.  We observed a signicant difference in tumor stage （stages 
I-II vs. stages III-IV） between CIMP-H and CIMP-N tumors （P＝ 0.0435）.  No 
significant differences were observed in clinicopathological characteristics （gender, 
age, location and tumor differentiation） among the CIMP phenotypes.  The progno-
ses of patients with a CIMP-H tumor is likely to be better than those with CIMP-
L or CIMP-N tumors, but these differences are not statistically signicant （P ＝
0.074 and P＝ 0.200）.  Our results suggest that CIMP may dene a subgroup of 
GCs with distinct biological features.
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Introduction
　Gastric cancer （GC） arises from native gastric or metaplastic mucosa and is one of the most 
common malignancies worldwide 1）.  Both genetic and epigenetic alterations in a variety of tumor 
suppressor and tumor-related genes have functional roles during carcinogenesis.  Changes in 
DNA methylation status are epigenetic events and represent the most common molecular altera-
tion in human neoplasia 2）.  These changes in DNA methylation in cancer are classied as either 
genome-wide hypomethylation or gene promoter hypermethylation.
　Promoter hypermethylation that leads to epigenetic silencing of multiple genes is an important 
mechanism in gastrointestinal carcinogenesis.  Methylation of CpG dinucleotide-rich areas, termed 
CpG islands, occurs within the promoters of approximately 60% of human genes 3）.  These CpG 
Original
1）Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1—5-8 Hatanodai, Shinagawa-
ku, Tokyo 142-8666, Japan.
2）Department of Pathology, Clinico-diagnostic Pathology, Showa University School of Medicine.
Masayuki TOJO, et al128
islands are usually associated with long-term, irreversible, epigenetic silencing of X-linked and 
imprinted genes as well as tumor-related genes 2）.  The concordant hypermethylation of multiple 
genes is termed the CpG island methylator phenotype （CIMP）, and has been described in 
various cancers 4-7）.  Recent studies have demonstrated that GCs can be classied as CIMP-high 
（CIMP-H）, CIMP-low （CIMP-L） and CIMP-negative （CIMP-N） and that GCs with CIMP-H 
are associated with proximal tumor location, Epstein-Bar virus infection status and longer patient 
survival time 8）.
　The aim of this study was to evaluate the status of CIMP in primary GCs and to characterize 
the relationships between methylation status and clinicopathological features.
Materials and Methods
Patients and specimens
　We collected a total of 105 primary GCs and 74 normal gastric mucosal tissues from 105 
patients.  All tissue specimens were obtained by endoscopic biopsy before treatment at Showa 
University Hospital.  Corresponding adjacent normal-mucosa tissue specimens were also obtained 
from each patient case.  Tumors were selected solely on the basis of availability.  The ethics 
committee of Showa University School of Medicine approved the collection of tissue specimens.
Tissue specimens and DNA preparation
　We examined 179 frozen tissue specimens （105 cancers and 74 adjacent normal-mucosa tissues） 
from 105 GC patients.  Frozen tissue specimens were harvested by endoscopic biopsy and stored 
at -80℃ until use.  DNA was isolated from the frozen tissue specimens using standard protein-
ase K-phenol-chloroform extraction 9） or a QIAamp DNA mini kit （QIAGEN, Inc., Germantown, 
MD, U.S.A.）.
Methylation-related genes and denition of CIMP
　We studied the methylation status of four clones: MINT1, MINT2, MINT25 and MINT31. 
Firstly, we treated DNA methylation as a continuous variable.  To dene CIMP, however, we 
converted the continuous values into categorical variables （positive/negative）, as defined by a 
methylation density greater than 15%.  We classied GCs into three groups （CIMP-H, CIMP-
L and CIMP-N）, based on their methylation status of the promoters in CpG islands of MINT1, 
MINT2, MINT25, and MINT31.  Tumors were classied as CIMP-H if three or more of these 
marker gene promoters were methylated ; as CIMP-L if one or two marker gene promoters 
were methylated ; and all other tumors were dened as CIMP-N.
Bisulte PCR and pyrosequencing analysis of DNA methylation
　Bisulte treatment was carried out as previously described 10）.  Aliquots of 2 or 3μL of bisul-
te-treated DNA were used as the template for the bisulte polymerase chain reaction （PCR）. 
The sequences of primers and the PCR conditions used to amplify specic DNA fragments of 
various target genes have been reported previously 11, 12）.  The protocol for pyrosequencing was 
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previously described in detail 13）.  Pyrosequencing measures the methylation status of several CpG 
sites in DNA.  Usually, these different sites show highly concordant methylation.  Therefore, we 
averaged the methylation percentage of all the CpG sites that we measured for each gene.
Data analysis and statistics
　Continuous variables （e.g., age） were analyzed using the Mann-Whitney test.  Categorical vari-
ables were compared between tumor groups using the χ2 test or Fisher’s exact test when testing 
small sample numbers.  Survival was assessed using the Kaplan-Meier method.  Survival curves 
were compared using the long-rank test.  All tests were two sided, and P＜ 0.05 was considered 
statistically signicant.
Results
CIMP status and clinicopathological characteristics
　The prevalence of CIMP-H, CIMP-L and CIMP-N among the 105 GCs was 22% （23/105）, 
52% （55/105） and 26% （27/105）, respectively.  Table 1 shows the relationship between CIMP 
status and clinicopathological characteristics of the patients with GC in this study.  We observed 
a signicant difference in stage （early vs. late stage） between CIMP-H and CIMP-N GC patients 
（P ＝ 0.0435）, whereas no signicant differences were observed in any other clinicopathological 
Table 1.  Clinicopathological characteristics of gastric carcinomas with CpG island 
methylator phenotype
CIMP-H
（N = 23）
CIMP-L / N
（N = 82） P value
Gender male 19 （82%） 50 （61%） 0.0534
female  4 （18%） 32 （39%）
Age （yr） mean 67.8   　　 66.8   　　 0.2452
（range） 　   （36-86） 　   （28-93）
Tumor location upper third 8 （34%） 31 （39%）
0.9651middle third 8 （34%） 31 （39%）
lower third 7 （32%） 24 （28%）
Macroscopic type type 0/2 12 （52%） 25 （31%） 0.278
type 3/4 11 （48%） 57 （69%）
Histology＊ tub/pap 10 （45%） 36 （44%）
0.9326por/sig/muc 12 （55%） 45 （56%）
missing 1　　　 1　　　
Clinical Stage＊＊ stage I-II 9 （39%） 15 （18%） 0.0355
stage III-IV 14 （61%） 67 （82%）
Therapy operation 6 （26%） 18 （22%）
0.4379chemotherapy 8 （35%） 32 （39%）
SR＋ CT 7 （30%） 26 （32%）
BSC 2 （ 9%）  6 （ 7%）
　＊ tub, tubular adenocarcinoma ; pap, papillary adenocarcinoma ; por, poorly differen-
tiated adenocarcinoma; sig, signet-cell carcinoma; muc, mucinous adenocarcinoma. 
＊＊ Stage was classied according to the International Union against Cancer TNM 
classification system. SR, surgical resection ; CT, chemotherapy ; BSC, best sup-
portive care.
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characteristics between patients with CIMP-H and CIMP-L/N GCs.
　The survival of patients with CIMP-H, CIMP-L and CIMP-N GCs was characterized using 
Kaplan-Meier analysis and was compared using the long-rank test （Fig. 1）.  Patients with CIMP-
H GCs tended to show longer survival time compared to those with CIMP-L or CIMP-N GCs 
（median survival : CIMP-H, 19 months ; CIMP-L, 13 months ; CIMP-N, 15 months, respectively）. 
It should be noted that these differences were not statistically signicant （P＝ 0.074 and P＝
0.200, respectively）.
Discussion
　Toyota et al 14） proposed a definition of CIMP status in GCs that is based on the DNA 
methylation of the MINT markers, which were originally identied from colon cancer cells.  GCs 
are classied as CIMP-L tumors and CIMP-H tumors, which are more likely to show distinct 
clinicopathological characteristics than CIMP-L tumors 8）.  Several reports 8，14-17） have shown the 
prevalence of CIMP-H in GCs to range from 24% to 41% using MINT markers.  The current 
study found CIMP-H in 22% of GCs using four MINT genes （MINT1, MINT2, MINT25 and 
MINT31）.  In other studies, CIMP was dened by the DNA methylation status of tumor-related 
genes, rather than MINT genes 18-20）.  The prevalence of CIMP-H tumors in the present study is 
similar to previous results obtained using MINT markers.  Although several sets of CIMP markers 
have been reported, CIMP-positive GCs are likely to dene distinct clinicopathological features.
　Kusano et al 8） reported that CIMP status is associated with the distinct clinicopathological 
features of GCs.  Their study indicated that GCs with CIMP-H more frequently showed proxi-
mal tumor location, diffuse histology, and longer patient survival time, compared with CIMP-L 
or CIMP-N8）.  In the current study, CIMP-H was detected signicantly more frequently in early 
（stages I-II） than late （stages III-IV） stage GCs.  No signicant differences were detected in 
any other clinicopathological characteristics, such as tumor location and differentiation, among the 
CIMP phenotypes.  The higher frequency of CIMP-H in early stage GCs may account for the 
better prognosis for those patients.  Chang et al 18） reported a lower frequency of lymph node 
metastasis in GCs with CIMP-H, which may reect the lower malignant potential of GCs with 
Fig. 1.  Survival was compared among patients who had GCs with CIMP-H, CIMP-L 
and CIMP-N as assessed using the Kaplan-Meier method.  Survival curves 
were compared using the log-rank test, but no significant differences were 
detected （CIMP-H vs. CIMP-L, P＝ 0.070 ; CIMP-H vs. CIMP-N, P＝ 0.200）.
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CIMP-H.  On the other hand, Mitsuno et al 21） recently reported a strong association between 
CIMP-H and cancer-related genes.  Patients with p16INK4a methylation were found to speci-
cally benet from 5-FU based adjuvant chemotherapy for GCs 21）.  Several reports 22-24） have sug-
gested that CHFR （Checkpoint with Forkhead-associated and RING nger domains） methylation 
might be a predictive marker for sensitivity of GCs to chemotherapy with microtubule inhibitors. 
Esteller et al 25） proposed that promoter hypermethylation of MGMT （O6-methylguanine DNA-
methyltransferase） was linked to the responsiveness of brain tumors to alkylating agents.  These 
positive relationships between the DNA methylation of cancer-related genes and therapeutic 
efcacy might be implicated in the longer survival time of GC patients with CIMP-H.  Our 
data shows that the survival time of GC patients with CIMP-H is likely to be longer than 
those with CIMP-L/CIMP-N GCs, but no statistical differences were observed in survival time 
among patients with different CIMP status.  It should be noted that the proportion of patients 
at stages III-IV in the current study is higher than in the study by Kusano et al （77% vs. 
56%, respectively）8）.  As shown in Figure 1, approximately half of the CIMP-H patients were 
terminated from the study for follow-up at 20 months.  Nine patients died after chemotherapy 
or surgical resection followed by chemotherapy （stage IV, eight patients ; stage IIIB, one patient）, 
three patients （all stage II） moved to another hospital.  These terminations from the study may 
have contributed to our failure to observe signicant differences in survival among patients with 
different CIMP status.  No signicant difference was found in other parameters such as tumor 
location and histologic differentiation between GCs with CIMP-H vs. CIMP-L/CIMP-N.  These 
observations could be explained by multiple factors, including : 1） about half of the samples 
in this study were stage IV GC, which more frequently show diffuse type cancer and shorter 
patient survival time than other types, independent of CIMP status 17）; 2） EB-virus status was not 
examined in this study because EBV-positive CIMP-H GCs are more likely to be diffuse carci-
nomas or to be located proximally in the stomach, compared with EBV-negative tumors 8）; 3） we 
used different CIMP-markers from previous studies.
　In summary, our data indicates that CIMP-H represents a specific subgroup of GCs with 
distinct biological features.  Clarication of the utility of CIMP status as a valuable prognostic 
marker for GCs awaits further study.
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